HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shepard, C. C. Articles by Fasal, P. Search for Related Content PubMed PubMed Citation Articles by Shepard, C. C. Articles by Fasal, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DAPSONE RIFAMPIN

Further Experience with the Rapid Bactericidal Effect of Rifampin on Mycobacterium Leprae^*

The effect of rifampin therapy in leprosy was studied in two clinical short-term trials in which skin punch biopsy specimens were taken at regular intervals for the inoculation of mice in order to monitor the decrease in proportion of viable Mycobacterium leprae in the patients' lesions. In a trial of rifampin in a dosage of 600 mg daily, the bacterial viability fell to undetectable levels in the first specimen taken after the start of therapy (at 3–4 days in 4 patients, 7–8 days in 9, and 14 days in 2). Dapsone-treated controls required 20 to more than 112 days for the same change. In a trial of a single dose of 1,500 mg rifampin, the viability fell to undetectable levels in the first specimen taken after the start of therapy also (at 3–5 days in all 14 patients).

Accepted for publication May 11, 1974.

^* Address reprint requests to: Charles C. Shepard, M.D., Leprosy and Rickettsial Diseases Section, Center for Disease Control, Atlanta, Georgia 30333.

This article has been cited by other articles:

				T. T. FAJARDO, R. S. GUINTO, R. V. CELLONA, R. M. ABALOS, E. C. DELA CRUZ, and R. H. GELBER A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am J Trop Med Hyg, March 1, 2006; 74(3): 457 - 461. [Abstract] [Full Text] [PDF]